These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
234 related articles for article (PubMed ID: 25708506)
1. Initial improvements when converting eyes with treatment-resistant exudative AMD to aflibercept are substantially diminished after increasing treatment intervals from 4 to 8 weeks. Jørstad ØK; Faber RT; Moe MC Acta Ophthalmol; 2015 Sep; 93(6):e510-1. PubMed ID: 25708506 [No Abstract] [Full Text] [Related]
2. Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab. Bakall B; Folk JC; Boldt HC; Sohn EH; Stone EM; Russell SR; Mahajan VB Am J Ophthalmol; 2013 Jul; 156(1):15-22.e1. PubMed ID: 23706500 [TBL] [Abstract][Full Text] [Related]
3. Aflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumab. Cho H; Shah CP; Weber M; Heier JS Br J Ophthalmol; 2013 Aug; 97(8):1032-5. PubMed ID: 23766432 [TBL] [Abstract][Full Text] [Related]
4. Switch to Aflibercept in the Treatment of Neovascular AMD: One-Year Results in Clinical Practice. Pinheiro-Costa J; Costa JM; Beato JN; Freitas-da-Costa P; Brandão E; Falcão MS; Falcão-Reis F; Carneiro ÂM Ophthalmologica; 2015; 233(3-4):155-61. PubMed ID: 25896317 [TBL] [Abstract][Full Text] [Related]
5. Intravitreal aflibercept treatment in eyes with exudative age-related macular degeneration following prior treatment with intravitreal ranibizumab. Narayan DS; Muecke J Indian J Ophthalmol; 2015 Nov; 63(11):832-6. PubMed ID: 26669334 [TBL] [Abstract][Full Text] [Related]
6. Visual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degeneration. Kumar N; Marsiglia M; Mrejen S; Fung AT; Slakter J; Sorenson J; Freund KB Retina; 2013 Sep; 33(8):1605-12. PubMed ID: 23549101 [TBL] [Abstract][Full Text] [Related]
7. Intravitreal aflibercept for ranibizumab-resistant exudative age-related macular degeneration with choroidal vascular hyperpermeability. Nomura Y; Yanagi Y Jpn J Ophthalmol; 2015 Jul; 59(4):261-5. PubMed ID: 25983109 [TBL] [Abstract][Full Text] [Related]
8. PIGMENT EPITHELIAL DETACHMENT RESPONSE TO AFLIBERCEPT IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION REFRACTORY TO RANIBIZUMAB: Time Course and Drug Effects. de Massougnes S; Dirani A; Ambresin A; Decugis D; Marchionno L; Mantel I Retina; 2016 May; 36(5):881-8. PubMed ID: 27115852 [TBL] [Abstract][Full Text] [Related]